Caribou Biosciences (CRBU)

• Market cap: $183M
• 1 day: 4.26%
• 5 days: 9.50%
• 1 month: -14.41%
• 3 months: 79.82%
• 6 months: 63.33%
• Year to date: 16.67%
• 1 year: -11.31%
• 5 years: -87.99%
• 10 years: -87.99%
• Sector: Healthcare
• Industry: Biotechnology

About: Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Employees: 147

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

58% more call options, than puts

Call options by funds: $152K | Put options by funds: $96K

10% more capital invested

Capital invested by funds: $46.5M [Q1] → $51.3M (+$4.82M) [Q2]

6% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 36

2% less funds holding

Funds holding: 130 [Q1] → 127 (-3) [Q2]

10.76% less ownership

Funds ownership: 54.03% [Q1] → 43.27% (-10.76%) [Q2]

40% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 43

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]